These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 22130786

  • 1. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
    Gorai I, Hattori S, Tanaka Y, Iwaoki Y.
    J Bone Miner Metab; 2012 May; 30(3):349-58. PubMed ID: 22130786
    [Abstract] [Full Text] [Related]

  • 2. Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women.
    Gorai I, Tanaka Y, Hattori S, Iwaoki Y.
    J Bone Miner Metab; 2010 Mar; 28(2):176-84. PubMed ID: 19657590
    [Abstract] [Full Text] [Related]

  • 3. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Moriishi M, Kawanishi H, Fukagawa M.
    Ther Apher Dial; 2011 Jun; 15 Suppl 1():62-6. PubMed ID: 21595855
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
    Fujiwara S, Hamaya E, Sato M, Graham-Clarke P, Flynn JA, Burge R.
    Clin Interv Aging; 2014 Jun; 9():1879-93. PubMed ID: 25395843
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 12. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy.
    Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R.
    Osteoporos Int; 2008 Apr; 19(4):529-35. PubMed ID: 17929072
    [Abstract] [Full Text] [Related]

  • 13. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
    Takata S, Abbaspour A, Yonezu H, Yasui N.
    J Med Invest; 2007 Feb; 54(1-2):35-40. PubMed ID: 17380012
    [Abstract] [Full Text] [Related]

  • 14. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
    Gao C, Qiao J, Li SS, Yu WJ, He JW, Fu WZ, Zhang ZL.
    Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 19. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BA, Bijlsma JW.
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [Abstract] [Full Text] [Related]

  • 20. The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis.
    You L, Sheng ZY, Chen JY, Pan L, Chen L.
    J Int Med Res; 2011 May; 39(1):302-10. PubMed ID: 21672334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.